Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up
| Autor: | Jean-Pierre Bassand, David J. Moliterno, Rick R. McClure, Michel E. Bertrand, Steen Dalby Kristensen, Franz-Josef Neumann, Steven J. Yakubov, Debabrata Mukherjee, Diego Ardissino, Gregg W. Stone, Howard C. Herrmann, Eric J. Topol |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
Acute coronary syndrome medicine.medical_treatment Abciximab Myocardial Infarction Immunoglobulin Fab Fragments medicine Myocardial Revascularization Humans Myocardial infarction Angioplasty Balloon Coronary business.industry Mortality rate Hazard ratio Percutaneous coronary intervention Stent Antibodies Monoclonal Tirofiban Middle Aged medicine.disease Survival Analysis Treatment Outcome Anesthesia Tyrosine Drug Therapy Combination Female Stents Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors medicine.drug Follow-Up Studies |
| Zdroj: | European heart journal. 26(23) |
| ISSN: | 0195-668X |
| Popis: | Aims Compared with placebo, abciximab has been associated with mortality reduction at late follow-up. The TARGET trial was performed to test whether tirofiban and abciximab provide similar efficacy outcomes among patients undergoing non-emergent, stent-based percutaneous coronary intervention. We report here the 1-year mortality of the study population. Methods and results In 18 countries at 149 hospitals, 4809 patients undergoing elective or urgent stent implantation were randomly assigned a bolus and infusion of tirofiban or abciximab. Ischaemic events were assessed at 30 days and 6 months and mortality was assessed at 1 year. We previously reported that abciximab was superior to tirofiban considering the composite rate of death or myocardial infarction at 30 days among all patients and at 6 months among those with an acute coronary syndrome (ACS). At 1-year follow-up death occurred in 46 (1.9%) patients who received tirofiban and 42 (1.7%) patients who received abciximab (hazard ratio 1.10, 95% CI 0.72–1.67; P =0.660). Mortality rates for patients with ACS were 2.3% with tirofiban vs. 2.2% with abciximab (hazard ratio 1.03, 95% CI 0.64–1.67; P =0.897) and those without ACS were 1.4 vs. 1.0% (hazard ratio 1.32, 95% CI 0.56–3.13; P =0.530). Conclusion At 1 year, tirofiban provided a similar level of survival benefit compared with abciximab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|